Table 3.
Comparison between patients with nausea and those without nausea during nintedanib treatment for idiopathic pulmonary fibrosis and risk factors for nausea.
| Characteristics | Overall | No | Yes | Monovariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | ||||
| 77 | 52 | 25 | |||||||
| Age | 0.508 | 0.187–1.383 | 0.224 | ||||||
| ≤74 | 44 | 27 | 17 | ||||||
| ≥75 | 33 | 25 | 8 | ||||||
| Sex | 1.534 | 0.376–6.249 | 0.741 | ||||||
| Female | 12 | 9 | 3 | ||||||
| Male | 65 | 43 | 22 | ||||||
| Smoking history | 1.333 | 0.321–5.528 | 0.988 | ||||||
| No | 11 | 8 | 3 | ||||||
| Yes | 66 | 44 | 22 | ||||||
| PS | 3.876 | 1.364–11.019 | 0.015 | 10.048 | 1.711–59.001 | 0.011 | |||
| 0–1 | 55 | 42 | 13 | ||||||
| 2–4 | 22 | 10 | 12 | ||||||
| mMRC | 2.769 | 1.014–7.564 | 0.044 | 1.876 | 0.272–7.219 | 0.255 | |||
| 0–1 | 52 | 39 | 13 | ||||||
| 2–4 | 25 | 13 | 12 | ||||||
| GAP index | 3.375 | 1.250–9.115 | 0.014 | 3.058 | 0.736–12.705 | 0.124 | |||
| ≤5 | 46 | 36 | 10 | ||||||
| ≥6 | 31 | 16 | 15 | ||||||
| BMI | 15.011 | 3.727–60.372 | <0.001 | 10.841 | 2.644–44.448 | 0.001 | |||
| <21.6 | 39 | 35 | 4 | ||||||
| ≥21.6 | 19 | 7 | 12 | ||||||
| PSL combination | 0.549 | 0.186–1.611 | 0.312 | 0.861 | 0.184–4.028 | 0.849 | |||
| No | 52 | 33 | 19 | ||||||
| Yes | 25 | 19 | 6 | ||||||
| Nintedanib dose | 3.400 | 0.864–5.790 | 0.065 | 22.965 | 2.754–191.464 | 0.004 | |||
| 300 mg/day | 51 | 31 | 20 | ||||||
| 200 mg/day | 26 | 21 | 5 | ||||||
OR: odds ratio, CI: confidence interval, PS: performance status, mMRC: modified Medical Research Council Dyspnea Scale, BMI: body mass index, PSL: prednisolone.